Related references
Note: Only part of the references are listed.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Membrane-Dependent Interaction of Factor Xa and Prothrombin with Factor Va in the Prothrombinase Complex
Shabir H. Qureshi et al.
BIOCHEMISTRY (2009)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
John H. Alexander et al.
CIRCULATION (2009)
Heart Disease and Stroke Statistics-2009 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Donald Lloyd-Jones et al.
CIRCULATION (2009)
Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
Jennifer Carreiro Zikria et al.
CURRENT OPINION IN HEMATOLOGY (2009)
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Double-blind studies are not always optimum for evaluation of a novel therapy:: the case of new anticoagulants
H. R. Buller et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Apixaban, an oral, direct and highly selective factor Xa inhibitor:: in vitro, antithrombotic and antihemostatic studies
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa
Job Harenberg et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2008)
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Donald J. P. Pinto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
What is all that thrombin for?
KG Mann et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Thrombin functions during tissue factor-induced blood coagulation
KE Brummel et al.
BLOOD (2002)
Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex
AR Rezaie
BLOOD (2001)
Share Paper
